| アブストラクト | PURPOSE: There is currently limited evidence for the optimal timing of triple therapy initiation in Japan, which is crucial for optimizing strategies for the effective treatment of chronic obstructive pulmonary disease (COPD). This study assessed the impact of prompt vs delayed initiation of triple therapy following a COPD exacerbation on clinical and economic outcomes in patients in Japan. PATIENTS AND METHODS: Retrospective cohort study of patients in the Medical Data Vision Co., Ltd. database initiating triple therapy as single-inhaler triple therapy (fluticasone furoate/umeclidinium/vilanterol or budesonide/glycopyrronium/formoterol) or multiple-inhaler triple therapy within 180 days of a moderate-to-severe exacerbation (index). For the main analysis, patients were categorized as prompt or delayed initiators, initiating triple therapy within 0-30 days or 31-180 days of index, respectively. Inverse probability of treatment weighting based on propensity scores was used to adjust for measured confounders between prompt and delayed cohorts. RESULTS: For the main analysis, 610 (60.3%) and 402 (39.7%) patients were prompt and delayed initiators, respectively. The rate of subsequent moderate-to-severe exacerbations following index exacerbation was numerically lower in prompt vs delayed initiators (weighted rate ratio 0.95, 95% confidence interval [CI]: 0.74-1.21; P = 0.6603). Time-to-first subsequent moderate-to-severe exacerbation increased significantly in prompt vs delayed initiators (weighted hazard ratio 0.77, 95% CI: 0.64-0.93; P = 0.0053). In patients indexed on a severe exacerbation, delayed initiation resulted in significantly higher 90-day all-cause readmissions vs prompt initiation (42.1% vs 30.6%; P = 0.0329 [weighted estimates]). Weighted healthcare resource utilization rates were numerically lower in prompt vs delayed initiators, and weighted direct costs (all cause and COPD-related) were significantly lower in prompt initiators. CONCLUSION: This real-world study demonstrated that earlier initiation of triple therapy resulted in several benefits in clinical outcomes for COPD and may also reduce the economic burden of COPD management in Japan. |
|---|
| ジャーナル名 | International journal of chronic obstructive pulmonary disease |
|---|
| Pubmed追加日 | 2023/12/13 |
|---|
| 投稿者 | Czira, Alexandrosz; Akiyama, Shoko; Ishii, Takeo; Wood, Robert P; Camidge, Lucinda J; Wallis, Hannah; Jennison, Thomas; Wild, Rosie A C; Yarita, Masao; Hashimoto, Kenichi; Rothnie, Kieran J; Ismaila, Afisi S |
|---|
| 組織名 | Value Evidence and Outcomes, R&D Global Medical, GSK, Brentford, Middlesex, UK.;Value Evidence and Outcomes, Japan Medical and Development, GSK, Tokyo, Japan.;Real-World Evidence, Adelphi Real World, Bollington, UK.;Value Evidence and Outcomes, R&D Global Medical, GSK, Collegeville, PA, USA.;Department of Health Research Methods, Evidence, and Impact, McMaster University,;Hamilton, ON, Canada. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/38089540/ |
|---|
